Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 19/20 | 0.55 |
| ▸ | CDK2 | P24941 | 19/20 | 0.55 |
| ▸ | CCNE2 | O96020 | 18/20 | 0.55 |
| ▸ | CDK4 | P11802 | 12/20 | 0.55 |
| ▸ | CCND1 | P24385 | 11/20 | 0.55 |
| ▸ | CDK1 | P06493 | 10/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 9/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.55 |
| ▸ | CCNB3 | Q8WWL7 | 9/20 | 0.55 |
| ▸ | CCND2 | P30279 | 1/20 | 0.48 |
| ▸ | CCND3 | P30281 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789785 | 0.77 | CDK2 (0.39) | CDK2 | |
| SCHEMBL2666164 | 0.76 | CCNE1 (0.69) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL16731888 | 0.73 | CCNE1 (0.68) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL5216993 | 0.70 | CCNE1 (1.00) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL5791573 | 0.70 | CCNE1 (0.44) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL9096131 | 0.70 | CCNE1 (0.61) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL13639769 | 0.69 | CCNE1 (0.70) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL5214383 | 0.68 | CCNE1 (0.61) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL5216840 | 0.67 | CCNE1 (0.67) | CCNE1CDK2CCNE2CDK4CCND1 | |
| SCHEMBL4731497 | 0.67 | CDK2 (1.00) | CCNE1CDK2CCNE2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303514-B9 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1303514-B1 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6897321-B2 | Process for preparing azacycloalkanoylaminothiazoles (LD 137e) | BRISTON MYERS SQUIBB COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040063767-A1 | Process for preparing azacycloalkanoylaminothiazoles (LD 137e) | CHEN BANG-CHI (US) | 2004-04-01 | — | — | US | disclosed |
| US-6639074-B2 | Reacting an alpha -substituted ketone with a cyclic alkylenetetramine in solvent(s) to form a quaternary ammonium salt; reacting with acid in solvent(s) form an alpha -amino ketone; reacting with acyl derivative; dehydrating | BRISTOL MYERS SQUIBB COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1303514-A1 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020099217-A1 | Process for preparing azacycloalkanoylaminothiazoles | CHEN BANG-CHI (US) | 2002-07-25 | — | — | US | disclosed |
| US-6414156-B2 | EFFICENT, NOTOXIC PROCESS OF MAKING NEW KEY INTERMEDIATE QUATERNARY AMMONIUM SALTS AND 2-OXAZOLYLALKYL SULFIDE DERIVATIVES AND AVOIDS THE REACTION OF A-HALOKETONES WITH AN AZIDE FOLLOWED BY REDUCING THE RESULTING A-AMINOKETONE | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2002010163-A1 | PROCESS FOR PREPARING AZACYCLOALKANOYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| US-20010006976-A1 | Process for preparing azacycloalkanoylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099217-A1 | Process for preparing azacycloalkanoylaminothiazoles | CDK9, CDK4, CDK6 | CCNE1 31/4885CDK2 15/4885CCNE2 42/4885 |
| US-20010006976-A1 | Process for preparing azacycloalkanoylaminothiazoles | CDK9, CDK4, CDK6 | CCNE1 31/4885CDK2 15/4885CCNE2 42/4885 |
| US-20040063767-A1 | Process for preparing azacycloalkanoylaminothiazoles (LD 137e) | CDK9, CDK4, CCNI | CCNE1 9/4885CDK2 19/4885CCNE2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.